Risk of incident diabetes after initiation of 5α-reductase inhibitor plus α-blocker combination therapy: A nationwide cohort study with age-specific analyses
Main finding · Incident diabetesResult — go to the resultAdjusted hazard ratio 1.13 95% CI 1.10–1.16Authors' conclusion
5ARI + AB initiation was associated with a modestly higher risk of incident diabetes, particularly among men aged < 65 years.
Study context
- Population
- Men aged ≥ 40 years with benign prostatic hyperplasia initiating 5ARI + AB or AB monotherapy during 2014–2018, Korean National Health Insurance Service database151,707 matched pairs
- Exposure
- 5ARI + AB combination therapy vs AB monotherapy
- Outcome
- Incident diabetes
Methodological detailsactive-comparator, new-user, propensity-score matched 1:1, stratified Cox models
- Active-comparator
- New-user
- Propensity-score matched 1:1
- Stratified Cox models
Main finding
As reported in the abstract
Adjusted hazard ratio
1.13
95% CI 1.10–1.16
By group
5ARI + AB
18.4 per 1,000 person-years
AB monotherapy
16.3 per 1,000 person-years
5ARI + ABvs AB monotherapy
adjusted HR 1.13 (95% CI 1.10–1.16)
Observational data: associations, not effects.
Further findings
| Outcome | Adjusted HR (95% CI) | |
|---|---|---|
| Incident diabetes, men aged < 65 years | 1.33 (1.27–1.39) | |
| 0.512Adjusted hazard ratio (log scale) |
Incident diabetes, men aged ≥ 65 years
- Estimates sensitive to competing-risk handling; close to the null after accounting for competing mortality
Sensitivity analyses
- Association persisted after a 12-month lag but attenuated in the as-treated analysis
Original publication
Risk of incident diabetes after initiation of 5α-reductase inhibitor plus α-blocker combination therapy: A nationwide cohort study with age-specific analyses. Diabetes Res Clin Pract. Published 24 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →